1Hansson L, Linholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999,354(9192): 1751—1756.
2Hansson L, lindholm LH, Niskanen L, et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension. the Captopril Prevention Project (CAPPP) randomised trial.Lancet 1999, 353 (9153): 611—616.
4The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med, 1997, 157(21): 2413—2446.
5Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. J Hypertens, 1999, 17 (2): 151—183.
7Hansson L,Zanchetti A,Carruthers SG,et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 35 (9118):1755—1762.
8Sica DA. Fixed-dose combination antihypertensive drugs : principles and practice. Cardiovasc Rev Rep,1997, 18 (9): 28—46.
9Moser M, Prisant LM. Low-dose combination therapy in hypertension. Am Fam Physician, 1997, 56(5): 1275—1282.
1Dahl of B, Lindholm LH, Hansson L,et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension(STOP-Hypertension). Lancet, 1991, 338(8778): 1281～1285
2Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and newantihypertensive drugs in elderly patients: cardiovascular mortality and morbidity theSwedish Trial in Old Patients with Hypertension-2 study. Lancet, 1999, 354(9192): 1751～1756
3Guidelines Subcommittee. 1999 World Health Organization-International Society ofHypertension guidelines for the management of hypertension. J Hypertens, 1999, 17(2): 151～183
4The sixth report of the Joint National Committee on Prevention, Detection,Evaluation, and Treatment of High Blood Pressure. Arch Intern Med, 1997, 157(21): 2413～2446
5Hansson L, lindholm LH, Niskanen L, et al. Effect of angiotensin - converting -enzyme inhibition compared with conventional therapy on cardiovascular morbidity andmortality in hypertension: the Csptepril Prevention Project (CAPPP) randomised trial.Lancet, 1993, 353(9153): 611～616
6Staessen JA, Thijs L, Fagard RH, et al. Calcium channel blockade and cardiovascularprognosis in the European trial on isolated systolic hypertension. Hyperension, 1998,32(3): 410～416
7UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducingrisk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ,1998, 317(7160): 713～720
8Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood - pressurelowering and low - dose aspirin in patients with bypertension: principal results of theHypertension Optimal Treatment (HOT) randomised trial. Lancet, 1998, 351(9118): 1755～1762
